Correction: Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase llb, randomised, double blind, placebo-controlled, dose-ranging study

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Miscellaneous
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456548/
https://www.ncbi.nlm.nih.gov/pubmed/32816784
http://dx.doi.org/10.1136/annrheumdis-2020-216980corr1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456548/
https://www.ncbi.nlm.nih.gov/pubmed/32816784
http://dx.doi.org/10.1136/annrheumdis-2020-216980corr1

Ejemplares similares